| MRK Stock | | | EUR 131.65 0.20 0.15% |
President
Dr. Roger M. Perlmutter, M.D. Ph.D. is Executive Vice President and President Merck Research Laboratories of the Company. He is responsible for the Companys global research and development efforts. Dr. Perlmutter was executive vice president and head of RD at Amgen Inc. from January 2001 to February 2012. During his tenure, Dr. Perlmutter oversaw the development and subsequent approval of a number of novel biologic and small molecule medicines in the areas of cancer, endocrinology, hematology, inflammation and osteoporosis. Prior to joining Amgen, he was executive vice president of worldwide basic research and preclinical development at Merck. He joined Merck as a senior vice president in February 1997. Before assuming leadership roles in industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington, where he also served as chairman of the Department of Immunology and was a Howard Hughes Medical Institute investigator. He is a Fellow of the American Academy of Arts and Sciences and an elected Fellow of the American Association for the Advancement of Science since 2013.
| Age | 67 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
Perlmutter graduated from Reed College in 1973 and received his M.D. and Ph.D. degrees from Washington University in St. Louis in 1979.
Merck Company (MRK) is traded on Berlin Exchange in Germany and employs 42 people.
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | |
| Pamela Craig, Independent Director | |
| Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | |
| Patricia Russo, Independent Director | |
| Franklin Clyburn, Executive Vice President Chief Commercial Officer | |
| Rita Karachun, Senior Vice President - Finance, Global Controller | |
| Christine Seidman, Independent Director | |
| Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | |
| Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | |
| Kathy Warden, Independent Director | |
| Thomas Cech, Independent Director | |
| Michael Nally, Executive Vice President, Chief Marketing Officer | |
| Paul Rothman, Independent Director | |
| Mary Coe, Independent Director | |
| Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | |
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | |
| Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | |
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | |
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | |
| Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer | |
| Peter Wendell, Independent Director | |
| Leslie Brun, Lead Independent Director | |
| Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | |
| Inge Thulin, Independent Director | |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Information and Resources on Investing in Merck Stock
When determining whether Merck Company is a good investment, qualitative aspects like company
management, corporate governance, and ethical practices play a significant role. A
comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock.
Highlighted below are key reports to facilitate an investment decision about Merck Company Stock: Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
You can also try the
Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.